

Bull, Bear & Beyond – Cereno Scientific: executive interview

In this interview, we speak with Sten Sørensen, CEO of [Cereno Scientific](#), about the company's strong start to 2026 and the key takeaways from the Q126 results. He provides updates on CS1 ahead of its planned Phase IIb trial in pulmonary arterial hypertension (PAH), discusses the advancement of CS014 in PH associated with interstitial lung disease (PH-ILD) and the ongoing pharmacokinetic bridging study, and explains the rationale for selecting antiphospholipid syndrome (APS) as the lead indication for CS585. Sten also highlights how the company's clinical programmes are aligned with the evolving regulatory landscape, helping to de-risk development, and comments on growing interest from potential pharmaceutical partners. He concludes by outlining the key milestones and catalysts investors can expect over the coming months, setting the stage for a newsflow-rich period.

Cereno Scientific (STO: CRNO-B) is a clinical-stage biotech focused on developing innovative treatments for rare diseases in the cardiovascular and pulmonary fields. Its pipeline is led by CS1 and CS014, HDAC inhibitors with disease-modifying potential in PAH and PH-ILD, respectively. Both candidates are supported by encouraging clinical data and are advancing towards later-stage clinical trials (Phase IIb for CS1 in June 2026 and Phase II for CS014 in Q127). A third asset, CS585, a prostacyclin receptor agonist, is currently in preclinical development for APS.

Listen on your preferred podcast player below:

- [Apple Podcast](#)
- [Spotify](#)
- [YouTube](#)
- [Zencastr](#)

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

